Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction

Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261

Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843

The Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease

Haffner, S. M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0343 · Cited by 193

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284

Thiazolidinediones

Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830

Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies

Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review

Grygiel-Górniak, B. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-17 · Cited by 1,079

Peroxisome Proliferator-Activated Receptor Alpha Target Genes

Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020

Sorting out the roles of PPAR in energy metabolism and vascular homeostasis

Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927

Therapeutic roles of peroxisome proliferator-activated receptor agonists

Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646

Japanese clinical practice guideline for diabetes 2019

Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545

Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes

Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients

Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 513

Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells

Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439

Safety considerations with fibrate therapy

Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408

Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk

Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041998 · Cited by 301

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264

Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233

Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Goff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.002 · Cited by 229

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk

Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227

Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome

Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208

Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator‐Activated Receptors

Sheng, X., Zhang, Y., Gong, Z., Huang, C., & Zang, Y. Q. (2008) · PPAR Research · doi:10.1155/2008/581348 · Cited by 203

Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes

Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176

Peroxisome Proliferator-Activated Receptor α Agonists Increase Nitric Oxide Synthase Expression in Vascular Endothelial Cells

Goya, K., Sumitani, S., Xu, X., Kitamura, T., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., Kasayama, S., & Kawase, I. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000118682.58708.78 · Cited by 174

Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial

Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167

Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.

Brunzell, J. D., & Ayyobi, A. F. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.011 · Cited by 155

Fibrates for primary prevention of cardiovascular disease events

Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147

Fibrates for secondary prevention of cardiovascular disease and stroke

Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142

Approaches to prevention of cardiovascular complications and events in diabetes mellitus

Coccheri, S. (2007) · Drugs · doi:10.2165/00003495-200767070-00005 · Cited by 139

Beyond Low-Density Lipoprotein Cholesterol

Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136

Untitled work

Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134

The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy

Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

The FIELD Study Investigators (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-13 · Cited by 103

Fenofibrate for patients with asymptomatic primary biliary cirrhosis

Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H., & Yamamoto, K. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.894 · Cited by 99

Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators

Han, S. H., Quon, M. J., & Koh, K. K. (2005) · Hypertension · doi:10.1161/01.hyp.0000187900.36455.4c · Cited by 98

Dyslipidemia

Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus

Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A. C., & Taskinen, M. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0751-8 · Cited by 68

Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis

Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials

Saha, S. A., & Arora, R. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.211 · Cited by 61

Combination statin-fibrate therapy: safety aspects

Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00917.x · Cited by 60

Diabetes and Cardiovascular Disease Prevention in Older Adults

Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50

Peroxisome proliferator-activated receptors—from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease

Bouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51

Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway

Maki, T., Maeda, Y., Sonoda, N., Makimura, H., Kimura, S., Maeno, S., Takayanagi, R., & Inoguchi, T. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.013 · Cited by 44

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice

Takei, K., Nakagawa, Y., Wang, Y., Han, S.-I., Satoh, A., Sekiya, M., Matsuzaka, T., & Shimano, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.02.003 · Cited by 43

Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Vakkilainen, J., Steiner, G., Ansquer, J.-C., Perttunen-Nio, H., & Taskinen, M.-R. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.627 · Cited by 40

Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia

Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40

The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis

Kim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36

Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.

(2005) · PubMed Central · Cited by 15